0000950170-24-029040.txt : 20240311
0000950170-24-029040.hdr.sgml : 20240311
20240311125459
ACCESSION NUMBER: 0000950170-24-029040
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fust Matthew K
CENTRAL INDEX KEY: 0001397266
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 24737287
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
ownership.xml
4
X0508
4
2024-03-07
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001397266
Fust Matthew K
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
true
false
false
false
true
Common Stock
2024-03-07
4
S
false
2550
50.89
D
24505
D
Common Stock
2024-03-07
4
S
false
2145
50.85
D
22360
D
Common Stock
2024-03-07
4
S
false
7500
50.88
D
14860
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Karah Parschauer, attorney-in-fact
2024-03-11